Scarica l'app Stockscreener
36.79
1.71%
-0.65
Springworks Therapeutics Inc Borsa (SWTX) Ultime notizie
SpringWorks started at outperform by Evercore ahead of FDA decision - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Now Covered by Evercore ISI - MarketBeat
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? - MSN
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Position Boosted by Victory Capital Management Inc. - MarketBeat
SpringWorks Therapeutics: Q3 Earnings Snapshot - AOL
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
Wedbush Has Negative Forecast for SWTX FY2024 Earnings - Defense World
When (SWTX) Moves Investors should Listen - Stock Traders Daily
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report - Yahoo Finance
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results - Simply Wall St
FY2024 Earnings Forecast for SWTX Issued By HC Wainwright - MarketBeat
Wedbush Has Negative Outlook for SWTX FY2024 Earnings - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Quarterly 10-Q Report - Quartzy
Los Angeles Capital Management LLC Boosts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Principal Financial Group Inc. Has $29.43 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highli - GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down on Analyst Downgrade - Defense World
SpringWorks Therapeutics Q3 2024 Results Overview - TipRanks
SpringWorks Therapeutics Inc (SWTX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
SpringWorks Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
HC Wainwright Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $74.00 - MarketBeat
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
SpringWorks Therapeutics to Present at Jefferies London Healthcare Conference | SWTX Stock News - StockTitan
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study - Yahoo Finance
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
SOPHiA GENETICS (NASDAQ:SOPH) vs. SpringWorks Therapeutics (NASDAQ:SWTX) Financial Review - Defense World
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q - GuruFocus.com
SpringWorks Therapeutics Announces Mirdametinib Data to be - GlobeNewswire
SpringWorks' Cancer Drug Shows Breakthrough 62% Response Rate, FDA Fast-Tracks Review | SWTX Stock News - StockTitan
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - Quantisnow
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating - The Bakersfield Californian
SpringWorks Therapeutics Announces Publication of the - GlobeNewswire
SpringWorks' Mirdametinib Shows Breakthrough 52% Response Rate in NF1-PN Trial | SWTX Stock News - StockTitan
Creative Planning Takes $254,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Tuesday - Defense World
Fiera Capital Corp Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - Defense World
Brokerages Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Price Target at $68.50 - Defense World
SpringWorks Therapeutics Announces Long-Term Efficacy and - GlobeNewswire
SpringWorks' OGSIVEO Shows 75.8% Tumor Reduction in 4-Year Treatment Data | SWTX Stock News - StockTitan
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 474 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) to Release Earnings on Tuesday - MarketBeat
SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - StockTitan
(SWTX) Trading Advice - Stock Traders Daily
SpringWorks Therapeutics Merits A Speculative Buy (NASDAQ:SWTX) - Seeking Alpha
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):